The delivery of biologically active (therapeutic) peptides and proteins into cells

Current Medicinal Chemistry

Volumn 18, Issue 9, 2011, Pages 1373-1379

  Grdisa, M ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Amphipathic peptides; CPP; CTP; Drug delivery; Protein transduction; TAT

Indexed keywords

ARGININE; CELL PENETRATING PEPTIDE; CENTRAL NERVOUS SYSTEM AGENTS; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYTOPLASMIC TRANSDUCTION PEPTIDE; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; GRAMICIDIN A; HYBRID PROTEIN; INSULIN; NANOPARTICLE; PENETRATIN; PEPTIDE DERIVATIVE; PROTEIN BCL XL; PROTEIN DERIVATIVE; PROTEIN P16; PROTEIN PEP1; PROTEIN YTA2; RECOMBINASE; STAT3 PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VALYLTHREONYLTRYPTOPHAN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE PERMEABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; MALIGNANT NEOPLASTIC DISEASE; NERVE CELL NECROSIS; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN DOMAIN;

CELL LINE, TUMOR; CELL MEMBRANE; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; HUMANS; PEPTIDES; PROTEINS; TRANS-ACTIVATORS;

EID: 79952782063     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795029591     Document Type: Article

References (114)

1. Anderson, W.F. Human gene therapy. Nature, 1998, 392, 25-30. (Pubitemid 28215190)
2. Luo, D.; Saltzman, W. Synthetic DNA delivery systems. Nat. Biotech., 2000, 18, 33-37. (Pubitemid 30041168)
3. Buchser, W.J.; Pardinas, J.R.; Shi, Y.; Bixby, J.L.; Lemmon, V.P. 96-Well electroporation method for transfection of mammalian central neurons. Biotechniques, 2006, 41, 619-622.
4. Peng, P.D.; Cohen, C.J.; Yang, S.; Hsu, C.; Jones, C.; Zhao, Y.; Zeng, Z.; Rosenberg, S.A.; Morgan, R.A. Efficient nonviral Sleeping Beauty transposon- based TCR gene transfer to peripheral blood lymphocytes confers antigen- specific antitumor reactivity. Gene Ther., 2009, 16, 1042-1049.
5. El-Sayed, A.; Futaki, S.; Harashima, H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment, AAPS J., 2009, 11, 13-22.
6. Wender, P.A.; Galliher, W.C.; Goun, E.L.; Jones, L.R.; Pillow, T.H. The design of guanidinium-rich transporters and their utilization mechanisms. Adv. Drug Deliv. Rev., 2008, 60, 452-472.
7. Derossi, D.; Joliot, H.A.; Chassaing, G.; Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes, J. Biol. Chem., 1994, 269, 10444-10450. (Pubitemid 24198241)
8. Nakase, I.; Hirose, H.; Tanak, G.; Tadokoro, A.; Kobayashi, S.; Takeuchi, T.; Futaki, S. Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis. Mol. Ther., 2009, 17, 1868-1876.
9. Wadia, J.; Dowdy, S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev., 2005, 57, 579-596. (Pubitemid 40255562)
10. El-Sayed, A.; Futaki, S.; Harashima, H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment, AAPS J. 2009, 11, 13-22.
11. Lo, S.L.; Wang, S. Intracellular protein delivery systems formed by noncovalent bonding interactions between amphipathic peptide carriers and protein cargos. Macromol. Rapid Commun., 2010, 31, 1134-1141. doi: 10.1002/marc.200900934
12. Cao, G.; Pei, W.; Ge, H.; Liang, Q.; Luo, Y.; Sharp, F.R.; Lu, A.; Ran, R.; Graham, S.H. Chen, J. In vivo delivery of Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci., 2002, 22, 5423-5431. (Pubitemid 35386464)
13. Nagahara, H.; Vocero-Akbani, A.M.; Snyder, E.L.; Ho, A.; Latham, D.G.; Lissy, N.A.; Becker-Hapak, M.; Ezhevsky, S.A.; Dowdy, S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27 Kip1 induces cell migration. Nat. Med., 1998, 4, 1449-1452. (Pubitemid 28553472)
14. Wadia, J.S.; Dowdy, S.F. Modulation of cellular functions by TAT mediated transduction of full length proteins. Curr. Protein Pept. Sci., 2003, 4, 97-104. (Pubitemid 36834009)
15. Ohta, Y.; Kamiya, T.; Nagai, M., Nagata, T.; Morimoto, N.; Miyazaki, K.; Murakami, T.; Kurata, T.; Takehisa, Y.; Ikeda, Y.; Asoh, S.; Ohta, S.; Abe, K. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res., 2008, 86, 3028-3037.
16. Kilic, K.; Kilic, U.; Hermann, D.M. TAT fusion proteins against ischemic stroke: Current status and future perspectives. Front. Biosci., 2006, 11, 1716-1721. (Pubitemid 43253389)
17. Snyder, E.L.; Saenz, C.C.; Denicourt, C.; Meade, B.R.; Cui, X.S.; Kaplan, L.M.; Dowdy, S.F. Enhanced targeting and killing of tumor cells expressing the CXC chemikone receptor 4 by transducible anticancer peptides. Cancer Res., 2005, 65, 10646-10650. (Pubitemid 41713328)
18. Michiue, H.; Tomizawa, K.; Matsushita, M.; Tamiya, T.; Lu, Y.F.; Ichikawa, T.; Date, I.; Matsui, H. Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett., 2005, 579, 3965-3969. (Pubitemid 40961896)
19. Choi, H.S.; Lee, S.H.; Kim, S.Y.; An, J.J.; Hwang, S.I.; Kim, D.W.; Yoo, K.Y.; Won, M.H.; Kang, T.C.; Kwon, H.J.; Kang, J.H.; Cho, S.W.; Kwon, O.S.; Choi, J.H.; Park, J.; Eum, W.S.; Cho, S.Y. Transduced Tat-alpasynuclein protects against oxidative stress in vitro and in vivo. J. Biochem. Mol. Biol., 2006, 39, 253-262. (Pubitemid 43854539)
20. Schwarze, S.R.; Dowdy, S.F. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci., 2000, 21, 45-48. (Pubitemid 30100337)
21. Asoh, S.; Ohsawa, I.; Mori, T.; Katsura, K.; Hiraide, T.; Katayama, Y.; Kimura, M.; Ozaki, D.; Yamagata, K.; Ohta, S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. USA, 2002, 99, 17107-17112. (Pubitemid 36034106)
22. Cai, S.R.; Xu, G.; Becker-Hapak, M.; Ma, M.; Dowdy, S.F.; McLeod, H.L. The kinetics and tissue distribution of protein transduction in mice. Eur. J. Pharm. Sci., 2006, 27, 311-319. (Pubitemid 43143256)
23. Green, M.; Loewenstein, P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT trans-activator protein. Cell, 1988, 55, 1179-1188. (Pubitemid 19020070)
24. Frankel, A.D.; Pabo, C.O. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell, 1998, 55, 1189-1193.
25. Xiao, K.J.; Rich, E. Multifaceted activities of the HIV-1 transactivator of transcription, TAT. J. Biol. Chem., 1988, 274, 28837-28840.
26. Vivès, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem., 1997, 272, 16010-16017. (Pubitemid 27265584)
27. Schmidt, N.; Mishra, A.; Lai, G.H.; Wong, G.C.L. Arginine-rich cellpenetrating peptides. FEBS Lett., 2010, 584, 1806-1813.
28. Wright, L.R.; Rothbard, J.B.; Wender, P.A. Guanidinium rich peptide transporters and drug delivery. Curr. Protein Pept. Sci., 2003, 4, 105-124. (Pubitemid 36834010)
29. Rothbard, J.B.; Jessop, T.C.; Wender, P.A. Adaptive translocation: The role of hydrogen bounding and membrane potential in the uptake of guanidiniumrich transporters into cells. Adv. Drug Deliv. Rev., 2005, 57, 495-504. (Pubitemid 40255557)
30. Ziegler, A.; Blatter, X.; Seeling, A.; Seeling, J. Protein transduction domains of HIV-1 and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic analysis. Biochemistry, 2003, 42, 9185-9194. (Pubitemid 36935428)
31. Goncalves, E.; Kitas, E.; Seeling, J. Binding of ologoarginine to membrane lipids and heparin sulphate: Structural and thermodynamic characterization of a cell-penetrating peptide. Biochemistry, 2005, 44, 2692-2702. (Pubitemid 40279574)
32. Mitchell, D.J.; Kim, D.T.; Steinman, L.; Fathman, C.G.; Rothbard, J.B. Polyarginine enters cells more efficiently than other polycationic homoplymers. J. Pept. Res., 2000, 56, 318-325.
33. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-rich peptides: An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem., 2001, 276, 5836-5840.
34. Rothbard, J.B.; Kreider, E.; VanDeusen, C.L.; Wright, L.; Wylie, B.I.; Wender, P.A. Arginine-rich molecular transporters for drug delivery: Role of backbone spacing in cellular uptake. J. Med.Chem., 2002, 45, 3612-3618. (Pubitemid 34856101)
35. Kim, D.; Jeon, C.; Kim, J.H.; Kim, M.S.; Yoon, C.H.; Choi, I.S.; Kim, S.H.; Bae, Y.S. Cytoplasmic transduction peptide (CTP): New approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp. Cell Res., 2006, 312, 1277-1288.
36. Chauhan, A.; Tikoo, A.; Kapur, A.K.; Singh, M. The taming of the cell penetrating domain of HIV Tat: Myths and realities. J. Controll. Release, 2007, 117, 148-162. (Pubitemid 46172502)
37. Brembilla, N.C.; Weber, J.; Rimoldi, D.; Pradervand, S.; Schütz, F.; Pantaleo, G.; Rüegg, C.; Quadroni, M.; Harshmann, K.; Doucey, M.A. C-Cbl expression levels regulate the functional responses of human central and effectors memory CD4 T cells. Blood, 2008, 112, 652-660.
38. Huang, S.F.; Liu, D.B.; Zeng, J.M.; Xiao, Q.; Luo, M.; Zhang, W.P.; Tao, K.; Wen, J.P.; Huang, Z.G.; Feng, W.I. Cloning, expression, purification and functional characterization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide. Protein Exp. Purif., 2009, 64, 167-178.
39. Huang, S.; Liu, D.; Zeng, J.; Yuan, Y.; Xiao, Q.; Sun, C.; Li, C.; Tao, K.; Wen, J.; Huang, Z.; Feng, W. Cloning, expression, purification, distribution and kinetics characterization of the bacterial β-galactosidase fused to the cytoplasmic transduction peptide in vitro and in vivo. Protein Exp. Purif., 2009, 68, 167-176.
40. Dietz, G.P.; Bahr, M. Delivery of bioactive molecules into the cells: The Trojan horse approach. Mol. Cell. Neurosci., 2004, 27, 85-131. (Pubitemid 39370094)
41. Futaki, S. Arginine-rich peptides: Potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm., 2002, 245, 318-325.
42. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. USA, 2000, 97, 13003-13008.
43. Thoren P.E.; Persson D.; Esbjorner, E.K.; Goksor, M.; Lincoln, P.; Norden, B. Membrane binding and translocation of cell-penetrating peptides. Bochem., 2004, 43, 3471-3489. (Pubitemid 38391703)
44. Thoren P.E.; Persson D.; Lincoln, P.; Norden, B. Membrane destabilizing properties of cell-penetrating peptides. Biophys. Chemist., 2005, 114, 169-179. (Pubitemid 40521515)
45. Futaki, S. Membrane-permeabile arginine-rich peptides and the translocation mechanisms. Adv. Drug Deliv. Rev., 2005, 57, 547-558. (Pubitemid 40255560)
46. Jones, S.W.; Christison, R.; Bundell, K.; Voyce, C.J.; Brockbank, S.M.; Newham, P.; Lindsay, M.A. Characterisation of cell-penetrating peptidemediated peptide delivery. Br. J. Pharmacol., 2005, 145, 1093-1102. (Pubitemid 43079982)
47. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic, 2007, 8, 848-866. (Pubitemid 46971632)
48. Räägel, H.; Säälik, P.; Hansen, M.; Langel, Ü.; Pooga, M. CPP-protein construct induce a population of non-acidic vesicles during trafficking through endo-lysosomal pathway. J. Contol. Release, 2009, 139, 108-117.
49. Richard, J.P.; Melikov, K.; Vivès, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chemomordik, I.V.; Lebleu, B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 2003, 278, 585-590. (Pubitemid 36043612)
50. Kaplan, I.M.; Wadia, J.S.; Dowdy, S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Cntrol. Release, 2005, 102, 247-253. (Pubitemid 40093789)
51. Nakase, I.; Niwa, M.; Takeuchi, T.; Sonomura, K.; Kaeabata, N.; Koike, Y.; Takehashi, M.; Tanak, S.; Ueda, K.; Simpson, J.C.; Jones, A.T.; Sugiura, Y.; Futaki, S. Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol. Ther., 2004, 10, 1011-1022. (Pubitemid 39625245)
52. Fittipaldi, A.; Ferrari A.; Zoppe, M.; Arcangeli, C.; Pellegrini, V.; Beltram, F.; Giacca, M. Cell membrane lipid rafts mediated calveolar endocytosis of HIV-1 tat fusion proteins. J. Biol. Chem., 2003, 278, 34141-34149. (Pubitemid 37553255)
53. Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, P.; Chernomordik, L.V. Cellular uptake of unconjugated TAT peptide involves clathrindependent endocytosis and heparin sulphate receptors. J. Biol. Chem., 2005, 280, 15300-15306. (Pubitemid 40562886)
54. Vandenbroucke, R.E.; De Smedt, S.C.; Demeester, J.; Sanders, N.N. Cellular entry pathway and gene transfer capacity of TAT-mediated lipoplexes. Biochim. Biophys. Acta, 2007, 1768, 571-579. (Pubitemid 46275589)
55. Fisher, R.; Kohler, K.; Fotin-Mleczek, M.; Brock, R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem., 2004, 279, 12625-12635. (Pubitemid 38445834)
56. Tünnemann, G.; Martin, R.M.; Haupt, S.; Patsch, C.; Edenhofer, F.; Cardoso, C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J., 2006, 20, 1775-1784. (Pubitemid 44933791)
57. Tünnemann, G.; Ter-Avetisyan, G.; Martin G.; Stockl, R.M.; Herrmann, M.; Cardoso, C. Live cell analysis of cell penetration ability and toxicity of oligoarginines in its current form. J. Pept. Sci., 2008, 14, 469-476. (Pubitemid 351540908)
58. Fretz, M.M.; Penning, N.A.; Al-Taei, S.; Futaki, S.; Takeuchi, T; Nakase, I.; Storm, G.; Jones, A.T. Temperature, concentration and cholesterol dependent translocation of L- And D-octaarginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem. J., 2007, 403, 335-342. (Pubitemid 46596590)
59. Ziegler, A.; Nervi, P.; Durrenbertger, M.; Seelig, J. The cationic cellpenetrating peptide Cpp(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: Optical, biophysical, and metabiloc evidence. Biochem., 2005, 44, 138-148. (Pubitemid 40095715)
60. Herce, H.D.; Garcia, A.E. Molecular dynamics stimulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. USA, 2007,104, 22420-22425.
61. Ter-Avetisyan, G.; Tünnemann, G.; Nowak, D.; Nitschke, M.; Herrmann, A.; Drab, M.; Cardoso, C.M. Cell entry of arginine-rich peptides is independent of endocytosis. J. Biol. Chem., 2009, 284, 3370-3378.
62. Vives, E.; Schmidt, J.; Pèlegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta, 2008, 1786, 126-138.
63. Eirksdottir, E.; Mager, I.; Lehto, T.; El Andaloussi, S., Langel, U. Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates. Bioconjugate Chem., 2010, 21, 1662-1672.
64. Peitz, M.; Jager, R.;, Patsch, C.; Jager, A.; Egert, A.; Schorle, H.; Edenhofer, F. Enhanced purification of cell-permeant Cre and germline transmission after transduction into mouse embryonic stem cells. Gemesis, 2007, 45, 508-517. (Pubitemid 47584209)
65. Nolden, L.;, Edenhofer, F.; Haupt, S.; Koch, P.;, Wunderlich, F.T.;, Siemen, H.; Brustle, O. Site-specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase. Nath. Methods, 2006, 3, 461-467. (Pubitemid 43811558)
66. Haupt, S.; Edenhofer, F.; Peitz, M.; Leinhaas, A.; Brustle, O. Stage-specific conditional mutagenesis in mouse embryonic stem cell-derived neural cells and postmitotic neurons by direct delivery of biologically active Cre recombinase. Stem Cells, 2007, 25, 181-188. (Pubitemid 46052989)
67. Stock, K.; Nolden, L.; Edenhofer, F.; Quandel, T.; Brustle, O. Transcriptionfactor based modulation of neural stem cell differentiation using direct protein transduction. Cell. Mol. Life Sci., 2010, 67, 2439-2449.
68. Doeppner, T.R.; Dietz, G.H.P.; Aanbouri, M.E.; Gerber, J.; Witte, O.W.; Bähr, M.; Weise, J. TAT-Bcl-xL improves survival of neuronal precursor cells in the lesioned striatum after focal cerebral ischemia. Neurobiol. Disease, 2009, 34, 87-94.
69. Gump, J.M.; Dowdy, S.F. TAT transduction: The molecular mechanism and therapeutic prospects. Trends Mol. Med., 2007, 13, 443-448. (Pubitemid 47562310)
70. Chen, L.; Harrison, S.D. Cell-penetrating peptides in drug development enabling intracellular targets. Biochem. Soc. Trans., 2007, 35, 821-825. (Pubitemid 47310376)
71. K.M. Wagstaff, D.A. Jans, Protein transduction: Cell-penetrating peptides and their therapeutic applications, Curr. Med. Chem., 2006, 13, 1371-1387.
72. Edenhofer, F. Protein transduction revisited: Novel insights into the mechanism underlying intracellular delivery of proteins. Curr. Pharm. Des., 2008, 14, 3628-3636.
73. Domashenko, A.D.; Danet-Desnoyers, G.; Aron, A.; Carroll, M.P.; Emerson, S.G. TAT-mediated transduction of NF-Ya peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic cells. Blood, 2010, 14, 2676-2683.
74. Faruque, O.M.; Le-Nguyen, D.; Lajoix, A.D.; Vives, E.; Petit, P.; Bataille, D.; Hani, E.-H. Cell-permeable peptide-based disruption of endogenous PKA-AKAP complex: A tool for studying the molecular roles of AKAPmediated PKA subcellular anchoring. Am. J. Physiol. Cell Physiol., 2009, 296, C306-C316.
75. Patel, H.H.; Hamuro, L.L.; Chun, B.J.; Kawaraguchi, Y.; Quick, A.; Rebolledo, B.; Pennypacker, J.; Thurston, J.; Rodrigez-Pinto, N.; Self, C.; Olson, G.; Insel, P.A.; Giles, W.R.; Taylor, S.S.; Roth, D.M. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)- conjugated A-kinase-anchoring peptide reduces cardiac function. J. Biol. Chem., 2010, 285, 27632-27640.
76. Tan, M.; Lan, K-H.; Yao, J.; Lu, C-H.; Sun, M.; Neal, C.L.; Lu, J.; Yu, D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducer and activator of transcription 3-blocking peptide. Cancer Res., 2006, 66, 3764-3772.
77. Baker, R.D.; Howl, J.; Nicholl, I.D. A sychnological cell penetrating peptide mimic p21(WAF1/CIP1) is pro-apoptogenic. Peptides, 2007, 28, 731-740. (Pubitemid 46349324)
78. Viehl, C.T.; Becker-Hapak, M.; Lewis, J.S.; Tanaka, Y.; Liyanage, U.K.; Linehan, D.C.; Eberlein, T.J.; Goedegebuure, P.S. A TAT fusion proteinbased vaccine for breast cancer. Ann. Surg. Oncol., 2005, 12, 1-9.
79. Kanki, K.; Ishijima, Y.; Watanabe, Y. Preparation of an artificial cell cycle progression with a novel mechanism. Biol. Pharm. Bull., 2009, 32, 1917-1920.
80. Patsch, C.; Peitz, M.; Otte, D.M.; Kessler, D.; Jungverdorben, J.; Wunderlich, T.F.; Brüstle, O.; Zimmer, A.; Edenhofer, F. Engineering cellpenetrating FLP recombinase for tightly controlled inducible and reversible overexpression in embryonic stem cells. Stem Cells, 2010, 28, 894-902.
81. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med., 1999, 27, 922-935. (Pubitemid 29507466)
82. Towsend, D.M.; Tew, K.D.; Tapiero, H. The impertance of glutathione in human disease. Biomed. Pharmacother., 2003, 57, 145-155.
83. Backos, D.S.; Brocker, C.N.; Franklin, C.C. Manipulation of cellular biosynthetic capacity via TAT-mediated protein transduction of wild-type or a dominant.negative mutant of glutamate cysteine ligase alters cell sensitivity to oxidant-induced cytotoxicity. Toxicol. Appl. Pharmacol., 2010, 243, 35-45.
84. Kwon, H.Y.; Eum, W.S.; Jang, H.W.; Kang, J.H.; Ryu, J.; Ryong Lee, B.; Jin, L.H.; Park, J.; Choi, Y. Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 Tat protein basic domain into mammalian cells. FEBS Lett., 2000, 485, 163-167.
85. Jin, L.H.; Bahn, J.H.; Eum, W.S.; Kwon, H.Y.; Jang, S.H.; Han, K.H.; Kang, T.C.; Won, M.H.; Kang, J.H.; Cho, S.W.; Park, J.; Choi, Y.S. Transduction of human catalase mediated by HIV-1 TAT protein basic domain and arginine- rich peptides into mammalian cells. Free Radic. Biol. Med., 2001, 31, 1509-1519. (Pubitemid 33145321)
86. Eum, W.S.; Choung, I.S.; Kim, A.Y.; Lee, Y.J.; Kang, J.H.; Park, J.; Lee, K.S.; Kwon, H.Y.; Choi, S.Y. Transduction efficacy of Tat-Cu,Znsuperoxide dismutase is enhanced by cooper ion recovery of the fusion protein. Mol. Cells, 2002, 13, 334-340. (Pubitemid 41583038)
87. Watanabe, N.; Iwamoto, T.; Bowen, K.D.; Dickinson, D.A.; Torres, M.; Forman, H.J. Bio-effectiveness of Tat-catalase conjugate: A potential tool for the identification of H2O2-dependent cellular signal transduction pathways. Biochem. Biophys. Res. Commun., 2003, 303, 287-293. (Pubitemid 36338238)
88. Eum, W.S.; Choung, I.S.; Li, M.Z.; Kang, J.H.; Kim, D.W.; Park, J.; Kwon, H.Y.; Choi, S.H. HIV-1 Tat-mediated protein transduction of Cu,Znsuperoxide dismutase into pancreatic beta cells in vitro and in vivo. Free Radic. Biol. Med., 2004, 37, 1339-349.
89. Song, H.Y.; Lee, J.A.; Ju, S.M.; Yoo, K.Y.; Won, M.H.; Kwon, H.J.; Eum, W.S.; Jang, S.H.; Choi, S.Y.; Park, J. Topical transduction of superoxide dismutase mediated by HIV-1 Tat protein transduction domain ameliorates 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice. Biochem. Pharmacol., 2008, 75, 1348-1357.
90. Brooks, N.A.; Pouniotis, D.S.; Tang, C.K.; Apostolopoulos, V.; Pietersz, G.A. Cell-penetrating peptides: Application in vaccine delivery. Biochim. Biophys. Acta, 2010, 1805, 25-34.
91. Lundin, P.; Johansson, H.; Guterstam, P.; Holm, T.; Hansen, M.; Langel, U.; El Andaloussi, S. Distinct uptake routes of cell penetrating peptides conjugates. Bioconjug. Chem., 2008, 19, 2535-2542.
92. Christiaens, B.; Symoens, S.; Vanderheyden, S.; Engelborghs, Y.; Joliot, A.; Prochiantz, A.; Vandekerekhove, J.; Rosseneu, M.; Vanloo, B. Tryptophane fluorescence study of the interaction of penetratin peptides with model membranes. Eur. J. Biochem., 2002, 269, 2918-2926. (Pubitemid 34754020)
93. Dom, G.; Shaw-Jackson, C.; Matis, C.; Bouffioux, O.; Picard, J.; Prochiantz, A.; Mingeot-Leclercq, M.; Brasseur, R.; Rezsohazy, R. Cellular uptake of Anntenapedia Penetratin peptides is a two-step process in which phase transfer precedes a tryptophane-dependent translocation. Nucl. Acid Res., 2003, 31, 556-561. (Pubitemid 36175944)
94. Binder, H.; Lindblom, G. Charge-dependent translocation of the Trojan peptide penetratin across lipid membranes. Biophys. J., 2003, 85, 982-995. (Pubitemid 36909662)
95. Aroui, S.; Brahim, S.; Waard, M.D.; Kenani, A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cellpenetrating peptides in different cell lines: A comparative study. Biochem. Biophys. Res. Comm., 2010, 1, 391419-391425.
96. Aroui, S.; Brahim, S.; Harnelin, J.; De Waard, M.; Brèard, J.; Kenani, A. Conjugation of doxorubicin to cell-penetrating peptides sensitized human brest MDA-MB 231cancer cells to endogenous TRAIL-independent apoptosis. Apoptosis, 2009, 11, 1352-1365.
97. Aroui, S.; Brahim, S.; Harnelin, J.; De Waard, M.; Brèard, J.; Kenani, A. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human brest cancer cell line MDA-MB 231. Cancer Lett., 2009, 285, 28-38.
98. Aroui, S.; Mili, D.; Brahim, S.; Harnelin, J.; De Waard, M.; Kenani, A. Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by mechanism involving c-Jun NH2-terminal kinase. Biochem. Biophys. Res. Comm., 2010, 396, 908-914.
99. Khafagy, El-S.,; Morishita, M.; Ida, N.; Nishio, R.; Isowa, K.; Takayama, K. Structural requirements of penetratin absortion enhancement efficiency for insulin delivery. J. Controll. Release, 2010, 143, 302-310.
100. Kurzawa, L.; Pellerano, M.; Morris, M.C. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells. Biochim. Biophys. Act- Biomembr., 2010, 1798, 2274-2285.
101. Myrberg, H.; Lindgren, M.; Langel, Ü. Protein delivery by the cellpenetrating peptide YTA2. Bioconjugate Chem., 2007, 18, 170-174. (Pubitemid 46146007)
102. Morris, M.C.; Depollier, J.; Mery, F.; Heitz, F.; Divita, G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol., 2001, 19, 1173-1176. (Pubitemid 33115705)
103. Deshayes, S.; Heitz, A.; Morris, M.C.; Charnet, P.; Divita, G.; Heitz, F. Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry, 2004, 43, 1449-1457. (Pubitemid 38200550)
104. Munoz-Morris, M.A.; Heitz, F.; Divita, G.; Morris, M.C. The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem. Biophys. Res. Commun., 2007, 355, 877-882. (Pubitemid 46366909)
105. Gros, E.; Deshayes, S.; Morris, M.C.; Adrian-Herrada, G.; Depollier, J.; Heitz, F.; Divita, G. Generation of carrier peptides for the delivery of nucleic acid drugs in primary cells. Biochim. Biophys. Acta, 2006, 1758, 384-393.
106. Wang, M.H.; Frishman, L.J.; Otteson, D.C. Intracellular delivery of proteins into mouse Muller glia cells in vitro and in vivo using Pep-1 transfection reagent. J. Neurosci. Meth., 2009, 177, 403-419.
107. Gallo, G. Making proteins into drugs: Assisted delivery of proteins and peptides into living neurons. Meth. Cell Biol., 2003, 71, 325-338.
108. Aoshiba, K.; Yokohori, N.; Nagai, A. Alveolar wall apoptosis caused lung destruction and emphysematous changes. Am. J. Respir. Cell Mol. Biol., 2003, 28, 555-562. (Pubitemid 36543402)
109. Kondo, E.; Seto, M.; Yoshikawa, K.; Yoshino, T. Highly efficient delivery of p16 anti-tumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. Mol. Cancer Ther., 2004, 3, 1623-1630. (Pubitemid 40136718)
110. Kondo, K.; Tanak, T.; Miyake, T.; Ichimura, T.; Hirai, M.; Adachi, M.; Yoshikawa, K.; Ichimura, K.; Ohara, N.; Moriwaki, A.; Date, I.; Ueda, R.; Yoshino, T. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines. Mol. Cancer Ther., 2008, 7, 1461-1471.
111. Wu, C.; Lo, S.L.; Boulaire, J.; Hong, M.L.; Beh, H.M.; Leung, D.S.; Wang, S. A peptide-based carrier for intracellular delivery of proteins into malignant glial cells in vitro. J. Control. Release, 2008, 130, 140-145.
112. Bais, M.V.; Kumar, S.; Tiwari, A.K.; Kataria, R.S.; Nagaleekar, V.K.; Shrivastava, S.; Chindera, K. Novel Rath peptide for intracellular delivery of protein and nucleic acids, Biochem. Biophys. Res. Commun., 2008, 370, 27-32.
113. Stoilova, T.B.; Kovalchuk, S.I.; Egorova, N.S.; Surovoy, A.Y.; Ivanov, V.T. Gramicidin A-based peptide vector for intacellular protein delivery. Biochim. Biophys. Acta., 2008, 1778, 2026-2031.
114. Konate, K., Crombez, L.; Deshayest, S.; Decaffmeyer, M.; Thomas, A.; Brasseur, R.; Aldrian, G.; Heitz, F.; Divita, G. Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry, 2010, 49, 3393-3402.